A

Arcellx Inc
NASDAQ:ACLX

Watchlist Manager
Arcellx Inc
NASDAQ:ACLX
Watchlist
Price: 77.68 USD 6.84% Market Closed
Market Cap: 4.3B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ACLX stock under the Base Case scenario is 53.26 USD. Compared to the current market price of 77.68 USD, Arcellx Inc is Overvalued by 31%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ACLX Relative Value
Base Case
53.26 USD
Overvaluation 31%
Relative Value
Price
A
Worst Case
Base Case
Best Case

Valuation Multiples

75.5
P/S
P/S
Price to Sales
75.5
vs History
6
vs Industry
24
Median 3Y
31.7
Median 5Y
29.9
Industry
7.6
Forward
86
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-20.7
Median 5Y
-19.1
Industry
24.3
Forward
-18.8
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
11
Median 3Y
-10.9
Median 5Y
-9.3
Industry
21.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
8
Median 3Y
-12.9
Median 5Y
-10.3
Industry
22.3
More Details
11
P/B
P/B
Price to Book Value
11
vs History
0
vs Industry
11
Median 3Y
6.9
Median 5Y
6.6
Industry
3.1
More Details
67.5
EV/S
EV/S
Enterprise Value to Sales
67.5
vs History
4
vs Industry
22
Median 3Y
26.3
Median 5Y
24.5
Industry
8
Forward
77
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.4
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-15.7
Median 5Y
-15
Industry
5.7
Forward
-16
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-15.5
Median 5Y
-14.6
Industry
6
Forward
-15.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
12
Median 3Y
-8.1
Median 5Y
-6.5
Industry
7
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
9
Median 3Y
-7.7
Median 5Y
-6.2
Industry
5
More Details
23.5
EV/IC
EV/IC
Enterprise Value to IC
23.5
vs History
15
vs Industry
9
Median 3Y
18.6
Median 5Y
14.9
Industry
5.2
More Details

Multiples Across Competitors

ACLX Competitors Multiples
Arcellx Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Arcellx Inc
NASDAQ:ACLX
4.3B USD 75.5 -22.9 -18.5 -17.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 813 875.7 -160 712.3 -195 156 -192 929.1
US
Abbvie Inc
NYSE:ABBV
389B USD 6.7 104.5 17 24.7
US
Amgen Inc
NASDAQ:AMGN
152.1B USD 4.4 23 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
146.4B USD 5.1 23.2 10.8 14.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 083.4 -531.6 -578.9 -563.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.8B USD 8.9 28 20.6 21.6
AU
CSL Ltd
ASX:CSL
101.1B AUD 4.3 22.4 14.8 18.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
61.4B USD 24.9 -192.3 -481.4 -330.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.5B USD 4.3 13.6 12.2 13.7
NL
argenx SE
XBRU:ARGX
40.1B EUR 15.4 36.7 88.2 92.4
P/S Multiple
Revenue Growth P/S to Growth
US
A
Arcellx Inc
NASDAQ:ACLX
Average P/S: 3 074 191.7
75.5
36%
2.1
FR
Pharnext SCA
OTC:PNEXF
33 813 875.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.4
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
E
Epizyme Inc
F:EPE
2 083.4
N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
8.9
10%
0.9
AU
CSL Ltd
ASX:CSL
4.3
6%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
24.9
41%
0.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.3
5%
0.9
NL
argenx SE
XBRU:ARGX
15.4
43%
0.4
P/E Multiple
Earnings Growth PEG
US
A
Arcellx Inc
NASDAQ:ACLX
Average P/E: 35.9
Negative Multiple: -22.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 712.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
104.5
88%
1.2
US
Amgen Inc
NASDAQ:AMGN
23
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
23.2
191%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.6 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
N/A N/A
AU
CSL Ltd
ASX:CSL
22.4
14%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -192.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
6%
2.3
NL
argenx SE
XBRU:ARGX
36.7
32%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
Arcellx Inc
NASDAQ:ACLX
Average EV/EBITDA: 26
Negative Multiple: -18.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 156 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.8
6%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.9 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.6
17%
1.2
AU
CSL Ltd
ASX:CSL
14.8
10%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -481.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.2
9%
1.4
NL
argenx SE
XBRU:ARGX
88.2
727%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
Arcellx Inc
NASDAQ:ACLX
Average EV/EBIT: 29.1
Negative Multiple: -17.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 929.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.8
12%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.5 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.6
17%
1.3
AU
CSL Ltd
ASX:CSL
18.5
14%
1.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -330.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.7
12%
1.1
NL
argenx SE
XBRU:ARGX
92.4
N/A N/A

See Also

Summary
ACLX intrinsic value, competitors valuation, and company profile.
DCF Valuation
ACLX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ACLX stock valuation using valuation multiples.
Wall Street Estimates
ACLX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ACLX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 281,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.